• 1. Evidence for the intrinsic nature of band-gap states electrochemically observed on atomically flat TiO2(110) surfaces?
  Shintaro Takata,Yoshihiro Miura Phys. Chem. Chem. Phys., 2014,16, 24784-24789
• 2. Emergence of cationic polyamine dendrimersomes: design, stimuli sensitivity and potential biomedical applications
  Partha Laskar,Christine Dufès Nanoscale Adv., 2021,3, 6007-6026
• 3. Excitonic channels from bio-inspired templated supramolecular assembly of J-aggregate nanowires?
  Daniel Messmer,Stefan Salentinig,Jakob Heier Nanoscale, 2019,11, 6929-6938
• 4. Distributed research: a new paradigm for undergraduate research and global problem solving?
  Bruce Parkinson Energy Environ. Sci., 2010,3, 509-511
• 5. Embedding heteroatoms: an effective approach to create porphyrin-based functional materials
  Norihito Fukui,Keisuke Fujimoto,Hideki Yorimitsu,Atsuhiro Osuka Dalton Trans., 2017,46, 13322-13341

Introduction to 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic Acid (CAS No. 1262006-62-1)

4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid, with the CAS number 1262006-62-1, is a sophisticated organic compound that has garnered significant attention in the field of chemical and pharmaceutical research. This compound belongs to the class of benzoic acid derivatives, characterized by its unique structural features that include a methoxy group at the para position relative to a trifluoromethyl group on one phenyl ring, and a methyl group on the other phenyl ring. Such structural motifs are often engineered to enhance biological activity, making this compound a promising candidate for various therapeutic applications.

The chemical structure of 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid consists of a central benzene ring substituted with a carboxylic acid group at one position and various aromatic groups at other positions. The presence of the 4-methoxy-3-trifluoromethylphenyl moiety imparts specific electronic and steric properties to the molecule, which can influence its interactions with biological targets. The methoxy group (-OCH?) is known for its ability to enhance solubility and metabolic stability, while the trifluoromethyl group (-CF?) is renowned for its ability to increase lipophilicity and binding affinity. The combination of these two groups, along with the methyl group (-CH?), creates a molecule with a balanced set of properties that make it attractive for drug discovery.

In recent years, there has been growing interest in developing novel compounds that can modulate biological pathways associated with inflammation, cancer, and neurodegenerative diseases. The structural features of 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid make it a potential candidate for such applications. For instance, studies have shown that benzoic acid derivatives can exhibit anti-inflammatory properties by inhibiting key enzymes such as cyclooxygenase (COX) and lipoxygenase (LOX). Additionally, the trifluoromethyl group is often incorporated into drug molecules to improve their pharmacokinetic profiles, including bioavailability and metabolic stability.

One of the most compelling aspects of 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid is its potential as a scaffold for further chemical modification. Researchers can leverage its unique structural framework to develop new analogs with enhanced biological activity or improved pharmacological properties. For example, modifications to the carboxylic acid group or the aromatic rings could lead to compounds with improved solubility or better cell permeability. Such modifications are crucial for optimizing drug candidates for clinical use.

The synthesis of 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid involves multi-step organic reactions that require careful optimization to ensure high yield and purity. Common synthetic routes include Friedel-Crafts alkylation followed by functional group transformations such as hydroxylation and fluorination. Advanced techniques in synthetic chemistry, such as cross-coupling reactions and palladium catalysis, can also be employed to construct the desired molecular framework efficiently. The availability of high-quality starting materials and reagents is essential for achieving reproducible results in these synthetic processes.

From a pharmaceutical perspective, the biological activity of 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid has been explored in various preclinical studies. These studies have highlighted its potential as an inhibitor of enzymes involved in inflammatory responses, such as COX-2 and LOX-5α. By modulating these enzymes, the compound may help reduce inflammation and alleviate symptoms associated with chronic inflammatory diseases like rheumatoid arthritis and inflammatory bowel disease. Furthermore, preliminary data suggest that it may have anticancer properties by interfering with signaling pathways that promote tumor growth and survival.

The pharmacokinetic profile of 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid is another area of interest. Due to its molecular structure, it is expected to exhibit good oral bioavailability and moderate metabolic stability. However, further studies are needed to fully characterize its absorption, distribution, metabolism, excretion (ADME) properties. Techniques such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), and nuclear magnetic resonance (NMR) spectroscopy are commonly used to analyze the compound's behavior in vitro and in vivo.

In conclusion, 4-(4-Methoxy-3-trifluoromethylphenyl)-3-methylbenzoic acid (CAS No. 1262006-62-1) is a structurally complex and biologically relevant compound with significant potential in pharmaceutical research. Its unique combination of functional groups makes it an attractive scaffold for developing novel therapeutic agents targeting various diseases. As research in this area continues to evolve, further insights into its biological activity and pharmacokinetic properties will undoubtedly emerge, paving the way for new treatments that improve human health.

• 1261998-14-4(2-[4-methoxy-3-(trifluoromethyl)phenyl]benzoic Acid)
• 1261968-80-2(2-(2-Methoxy-5-trifluoromethylphenyl)-6-methylbenzoic acid)
• 1261916-98-6(2-[4-methoxy-3-(trifluoromethyl)phenyl]-5-methylbenzoic Acid)
• 1261900-49-5(2-[4-methoxy-3-(trifluoromethyl)phenyl]-6-methylbenzoic Acid)
• 1261998-73-5(2-(2-Methoxy-5-trifluoromethylphenyl)benzoic acid)
• 1261936-45-1(2-(2-Methoxy-5-trifluoromethylphenyl)-5-methylbenzoic acid)
• 1261893-79-1(4-(4-Methoxy-3-trifluoromethylphenyl)benzoic acid)
• 1261896-41-6(3-(2-Methoxy-5-trifluoromethylphenyl)benzoic acid)
• 1261900-53-1(3-(4-Methoxy-3-trifluoromethylphenyl)-5-methoxybenzoic acid)
• 1261937-19-2(5-methoxy-2-[4-methoxy-3-(trifluoromethyl)phenyl]benzoic Acid)